#### **Supplementary Figure Legends**

#### **Supplementary Figure 1**

(**a-d**) Chemotherapeutic drugs do not induce DRAM-3 in Hep-G2 (**a**), A549 (**b**), LNCaP (**c**) or H1299 (**d**) cells. RT-qPCR analysis was performed on cells treated for 24h with Actinomycin D (2 nM), Etoposide (10  $\mu$ M) and Cisplatin (5  $\mu$ M). Each condition was measured in triplicate, and data displayed are means of DRAM-3/18S RNA levels from 3 experiments with the untreated condition (Co) normalised to 1. Error bars are SD.

# **Supplementary Figure 2**

(a) DRAM-3 and WIPI2 do not co-localize. Saos-2 pWZL DRAM-3 cells were with α-Myc-Tag and α-WIPI2 antibody for IF analysis. Images were taken with a Zeiss LSM710 microscope with 63x objective. (b) Quantification of Immunofluorescence analysis of DRAM-3 and LC3B overlap. Images of Saos-2 pWZL-DRAM-3 cells were taken with a Zeiss LSM710 microscope with 63x objective. Cells with medium overexpression (estimated 25% of the overall population; ~70% show low expression and ~5% high expression) were used for the experiment. Two cells per image in 17 images were analysed using the Zeiss Zen software co-localzation tool, after setting appropriate cut-offs. The results are represented as means; 'overall' is the average of all cells analysed, while 'high' denotes the mean of cells with apparently high costaining and 'low' the mean of cells with apparently low co-staining (1 each picked from each image). Error bars are SD. (c) A high proportion of DRAM-3 positive LC3 puncta are localized to autolysosomes/lysosomes. Saos-2 pWZL DRAM-3 cells retrovirally overexpressing EGFP-LC3

were generated and stained with  $\alpha$ -Myc-Tag and  $\alpha$ -LAMP2 antibodies for IF analysis. In control conditions, few LC3 puncta could be observed (data not shown) and so therefore treated cells with 100nM Bafilomycin A to cause autophagosome accumulation. Images were taken with a Zeiss LSM710 microscope using a 63x objective.

# **Supplementary Figure 3**

(a-b) DRAM-3 induction does not induce substantial levels of apoptosis. Saos-2 DRAM-3 tet-on cells were subjected to doxycycline treatment for 48h and then analysed for caspase 3 cleavage by western blotting (a). Treatment of cells with TNF and cycloheximide was used as a positive control. (b) Cells were also stained with Annexin V and propidium iodide prior to analysis by flow cytometry. Early apoptotic death (PI-/Annexin V+) is shown in the lower right quadrant. Late apoptotic death or necrotic death (PI+/Annexin V+) is shown in the upper right quadrant.
(c) DRAM-3 expression is attenuated in DRAM-3 Tet-On cells following DRAM-3 activation and 10 days recovery without doxycycline. DRAM-3 inducible cells were subjected to 7 days doxycycline treatment, followed by a 10 day doxycycline-free recovery growth and re-subjection to doxycycline. DRAM-3 induction is markedly attenuated in the second round of doxycycline treatment.

#### **Supplementary Figure 4**

(**a-c**) DRAM-3 overexpression affects autophagy in control conditions. Saos-2 cells were subjected to 1,2 and 4h of EBSS starvation (3 experiments). LC3B conversion and p62 were determined by Western blot analysis (**a-c**) and LC3BII/Actin levels were quantified using ImageJ (right panels). (**d-f**). Quantification of LC3B-II/Actin levels in wild-type (GFP Crispr) and

DRAM-3 Crispr knockout cells following treatement with chloroquine. Quantification of the blots is shown below each blot.

### **Supplementary Figure 5**

(a) DRAM-3 disruption does not change early endosome and lysosome appearance. EEA1 antibody was used to visualise early endosomes, and LAMP2 antibody to visualise lysosomes in Saos-2 CRISPR Control and DRAM-3 cells. Immunofluorescence analysis was performed on a Zeiss 710 confocal microscope with 63x objective. (b) DRAM-3 overexpression does not affect endocytic uptake of BSA. Saos-2 pWZL and pWZL DRAM-3 were serum- and amino acid-starved (EBSS) for 3h 30min, then BSA (1 mg/ml) was added back for different time points. Western blot analysis was performed to determine the endocytic uptake of BSA. (c) Uptake kinetics of (b). The uptake of each time point in the 2 cell lines was quantified from 3 experiments. Values displayed are means, error bars are SD.

## **Supplementary Figure 6**

(a) DRAM-3 overexpression protects from Glucose starvation-induced cell death. MDA-MB-231 cells containing pWZL Control and pWZL DRAM-3 contructs were subjected to 24h Glucose starvation (DMEM glucose free + 2% dialized FBS). The starvation media was exchanged after 24h and the surviving cells were grown in normal growth media for 3-4 days before staining them for colony formation with Giemsa modified stain. (b) Glucose-starvation induced cell death is mainly non-apoptotic. Saos-2 pWZL and pWZL DRAM-3 cells were subjected to 24h Glucose starvation with and without addition of apoptosis inhibitor 50μM z-

Vad-FMK (b). 4 µg/ml Cycloheximide (CHX) + 5ng/ml TNF- $\alpha$  (TNF) was used as an apoptosis-inducing positive control. (c) DRAM-3 expressing and vector control cells (pWZL) were treated as indicated and were then stained with Annexin V and propidium iodide prior to analysis by flow cytometry. Early apoptotic death (PI-/Annexin V+) is shown in the lower right quadrant. Late apoptotic death or necrotic death (PI+/Annexin V+) is shown in the upper right quadrant. (d) Crispr knockout of DRAM-3 does not decrease survival following glucose deprivation. Saos-2 control (GFP Crispr) and DRAM-3 Crispr knockout cells were subjected to 24h Glucose starvation (DMEM glucose free + 2% dialized FBS). The starvation media was exchanged after 24h and the surviving cells were grown in normal growth media for 3-4 days before staining for colony formation with Giemsa-modified stain. (e) Inhibition of autophagy by treatment with chloroquine does not affect cell death induced by glucose deprivation in either DRAM-3 expressing or vector control cells (pWZL). Cells were stained with Annexin V and propidium iodide prior to analysis by flow cytometry. Early apoptotic death (PI-/Annexin V+) is shown in the lower right quadrant. Late apoptotic death or necrotic death (PI+/Annexin V+) is

#### **Supplementary Figure 7**

DRAM-3 overexpressing cells show greater LC3B-II levels in control and glucose-starvation conditions. Saos-2 pWZL and pWZL DRAM-3 cells were subjected to 24h Glucose starvation (DMEM glucose free + 2% dialized FBS) and then analysed for LC3B conversion by western blotting. 3 experiments were quantified using ImageJ and the results were plotted as means of LC3BII/Actin levels, error bars are SEM.

# **Supplementary Figure 8**

*DRAM-3* is amplified in a number of tumour types. Using publically available datasets in cBioPortal (www.cBioPortal.org), *dram-3* genetic alterations were mapped in a range of cancer types.